MX2018005193A - Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. - Google Patents

Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.

Info

Publication number
MX2018005193A
MX2018005193A MX2018005193A MX2018005193A MX2018005193A MX 2018005193 A MX2018005193 A MX 2018005193A MX 2018005193 A MX2018005193 A MX 2018005193A MX 2018005193 A MX2018005193 A MX 2018005193A MX 2018005193 A MX2018005193 A MX 2018005193A
Authority
MX
Mexico
Prior art keywords
protein
dual function
pharmaceutical composition
same
present
Prior art date
Application number
MX2018005193A
Other languages
English (en)
Inventor
Hwan Kim Jun
LIM Seyoung
Seo Minji
Ho Choi Hyun
Kim Dohoon
Kyeong JU Mi
Young PARK Ju-
Gyun KIM Jong
Youn Nam Su
Gi Kim Seul
LIM Sangmyoun
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2018005193A publication Critical patent/MX2018005193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención provee una proteí­na de doble función preparada uniendo una proteí­na biológicamente activa y una proteí­na mutante de FGF a una región Fc de una inmunoglobulina, que tiene una eficacia farmacológica, duración in vivo y estabilidad proteica mejoradas. Una proteí­na de doble función de conformidad con la presente invención presenta eficacia farmacológica, duración in vivo y estabilidad proteica mejoradas, y una composición farmacóutica que contiene la proteí­na de doble función como ingrediente activo puede usarse eficazmente como agente terapóutico para diabetes, obesidad, dislipidemia, sí­ndrome metabólico, enfermedades del hí­gado graso no alcohólico, esteatohepatitis no alcohólica o enfermedades cardiovasculares.
MX2018005193A 2015-10-28 2016-10-28 Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. MX2018005193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150150576A KR20170049320A (ko) 2015-10-28 2015-10-28 이중 작용 단백질 및 이를 포함하는 약학적 조성물
PCT/KR2016/012300 WO2017074123A1 (en) 2015-10-28 2016-10-28 Dual function proteins and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
MX2018005193A true MX2018005193A (es) 2018-07-06

Family

ID=58630627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005193A MX2018005193A (es) 2015-10-28 2016-10-28 Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.

Country Status (13)

Country Link
US (2) US11136364B2 (es)
EP (1) EP3368555A4 (es)
JP (2) JP2019500013A (es)
KR (1) KR20170049320A (es)
CN (4) CN115925978A (es)
AU (1) AU2016346870B2 (es)
BR (1) BR112018008805A8 (es)
CA (1) CA3003115A1 (es)
HK (1) HK1257373A1 (es)
MX (1) MX2018005193A (es)
RU (1) RU2741345C2 (es)
WO (1) WO2017074123A1 (es)
ZA (1) ZA201802003B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170049320A (ko) 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR20170049319A (ko) 2015-10-28 2017-05-10 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
AU2017358289A1 (en) * 2016-11-10 2019-06-20 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
EA201992516A1 (ru) * 2017-04-21 2020-04-09 Юхан Корпорейшн Способ получения бифункциональных белков и их производных
CN116143939A (zh) * 2017-11-24 2023-05-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
WO2019154189A1 (en) 2018-02-08 2019-08-15 Sunshine Lake Pharma Co., Ltd. Fgf21 variant, fusion protein and application thereof
US20210275643A1 (en) * 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
US20220064244A1 (en) * 2019-03-05 2022-03-03 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
WO2021107689A1 (ko) * 2019-11-27 2021-06-03 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139763A1 (zh) * 2020-01-08 2021-07-15 上海翰森生物医药科技有限公司 Fgf21突变体蛋白及其融合蛋白
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN117510646A (zh) * 2022-08-03 2024-02-06 无锡市华盛康肽生物技术有限公司 一种双功能融合蛋白及其用途
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
CN101974090B (zh) 2003-06-12 2015-06-17 伊莱利利公司 Glp-1类似物融合蛋白质
EP1735340A2 (en) 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
CA2649751A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compound/glucagon antibody compositions
WO2008102923A1 (en) 2007-02-23 2008-08-28 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
EP3260129A1 (en) * 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CA2748593A1 (en) * 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
LT2393828T (lt) * 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
AR076541A1 (es) 2009-05-05 2011-06-22 Amgen Inc Mutantes de fgf21 y usos del mismo
CA2760674A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
US20120172298A1 (en) * 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
CN102791730A (zh) 2010-01-22 2012-11-21 诺沃—诺迪斯克有限公司 低度o-糖基化的fgf21的制备方法
CN103415300B (zh) 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
CN102558358A (zh) 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US9475856B2 (en) * 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
MX2015002985A (es) * 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
AU2014318579A1 (en) * 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR20170049319A (ko) 2015-10-28 2017-05-10 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR20170049320A (ko) 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
WO2018166461A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
EA201992516A1 (ru) 2017-04-21 2020-04-09 Юхан Корпорейшн Способ получения бифункциональных белков и их производных

Also Published As

Publication number Publication date
CN108350054A (zh) 2018-07-31
JP2019500013A (ja) 2019-01-10
ZA201802003B (en) 2019-05-29
CN116333160A (zh) 2023-06-27
KR20170049320A (ko) 2017-05-10
CN115925978A (zh) 2023-04-07
HK1257373A1 (zh) 2019-10-18
CA3003115A1 (en) 2017-05-04
EP3368555A1 (en) 2018-09-05
BR112018008805A8 (pt) 2019-02-26
CN108350054B (zh) 2022-09-02
US11136364B2 (en) 2021-10-05
JP2023011644A (ja) 2023-01-24
WO2017074123A1 (en) 2017-05-04
AU2016346870B2 (en) 2021-04-22
EP3368555A4 (en) 2019-11-20
RU2741345C2 (ru) 2021-01-25
CN115925979A (zh) 2023-04-07
US20200024318A1 (en) 2020-01-23
RU2018118025A3 (es) 2020-03-24
AU2016346870A1 (en) 2018-05-10
BR112018008805A2 (pt) 2018-10-30
RU2018118025A (ru) 2019-11-28
US20220002368A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
IL288204A (en) Protein-targeted compounds and their pharmaceutical preparations and their medical applications
WO2015051030A3 (en) Stabilized polypeptides and uses thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
EP3659585A4 (en) COMPOSITION FOR ADMINISTERING PHYSIOLOGICALLY ACTIVE SUBSTANCES INTO A BLOOD VESSEL
EA201492053A1 (ru) Белки фактора роста фибробластов 21
MX2014016107A (es) Derivados de tienopiridona utiles como activadores de ampk.
WO2017100700A3 (en) Peptides for renal therapy
WO2017194782A3 (en) Therapeutic targeting of non-cellular structures
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
WO2013009545A8 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
WO2013002580A3 (ko) 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
TN2018000038A1 (en) Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
WO2017041001A3 (en) Insulin immunoglobulin fusion proteins
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2022013566A (es) Anticuerpo.
NZ702342A (en) Pharmaceutical formulation
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.